Yash Vardhan Trivedi

Yash Vardhan Trivedi

Auto-generated profile, based on publicly available information

Yash Vardhan Trivedi

University of Miami

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2025 in Postgraduate Medicine
Verified
Journal Article
Closed access
RCRahul Chikatimalla
Rahul Chikatimalla
YTYash Vardhan Trivedi
Yash Vardhan Trivedi
NRNamita Ruhela
Namita Ruhela
SSShubhangi Singh
Shubhangi Singh
ALAmar Lal
Amar Lal
RJRohit Jain
Rohit Jain
Cardiovascular disease (CVD) and chronic kidney disease (CKD) are major global health concerns, with CKD significantly amplifying cardiovascular mortality. Statins, widely used to manage hyperlipidemia, are recognized for their lipid-lowering properties and additional benefits, including anti-inflammatory, antioxidant, and plaque-stabilizing effects. This review explores the multifaceted role of statins in cardiovascular and renal protection, particularly among CKD patients. This narrative review synthesizes evidence from clinical studies assessing the cardiovascular and renal outcomes of statin use in patients with CKD. It examines the effects of statins across various clinical scenarios, demographics, and comorbidities, with a focus on their impact on cardiovascular events, renal function. Statins significantly reduce all-cause mortality and major adverse cardiovascular events in patients with mild to moderate CKD, with evidence supporting their efficacy across diverse populations. Trials such as JUPITER and the Heart Protection Study highlight their cardiovascular benefits and potential to stabilize kidney function. In surgical settings, statins show promise in mitigating acute kidney injury through inflammatory pathway modulation. However, their impact on renal outcomes, such as proteinuria, albuminuria, and glomerular filtration rate, is inconsistent. High-dose statins, especially in advanced CKD, may carry risks including hematuria or rhabdomyolysis, particularly with improper dosing or drug interactions. Safety depends on statin type, dose, and renal function. Additionally, statins reduce the risk of contrast-induced nephropathy and slow CKD progression in select populations, though variability in study designs limits generalizability. Statins provide substantial cardiovascular benefits for CKD patients, but their renal effects remain uncertain. Future research should aim to optimize treatment strategies, including personalized regimens, to balance cardiovascular protection and renal safety effectively.

1 July 2025 in Southern Medical Journal
Verified
Journal Article
Closed access
YTYash Vardhan Trivedi
Yash Vardhan Trivedi
PMParth Munjal
Parth Munjal
BSBhupinder Singh
Bhupinder Singh
RKRhea Kanwar
Rhea Kanwar
AGAachal Gupta
Aachal Gupta
MDMd
Md
High-sensitivity C-reactive protein (hs-CRP) is a key marker of inflammation, predominantly produced by hepatocytes and various tissues, including intracardiac tissue, atherosclerotic plaques, and vascular smooth muscles. The biomarker serves as a crucial element of innate immunity and rises in response to various disease processes, including infections and cancers. This rise is triggered by the...

29 May 2026 in Medical Engineering & Physics
Verified
Journal Article
Open access
CLChangkye Lee
Changkye Lee
SZShijia Zhao
Shijia Zhao
WWWei Wu
Wei Wu
RBRakshita Ramesh Bhat
Rakshita Ramesh Bhat
PPPriyansh Patel
Priyansh Patel
YCYiannis S Chatzizisis
Yiannis S Chatzizisis
The objective of this study was to present and demonstrate the feasibility of a simplex deformable model (SDM) for patient-specific coronary stent simulations in two patient-specific cases. Patient-specific 3D artery anatomies were converted into triangular meshes and then transformed into 2-simplex meshes. For each vertex, three neighboring vertices were used to compute outward and inward normal vectors to model stent expansion and arterial wall resistance. Internal forces representing stent mechanics were computed during expansion, and external forces incorporating non-linear hyperelastic arterial behavior were applied after stent-wall contact. Two patient-specific arteries were simulated using the SDM framework, with the finite element method (FEM) as the reference. Relative to FEM, the SDM achieved 360–670 times faster computational time, and reduced vertex counts by 9.5–12.6 times. Bland–Altman analysis showed small mean biases in mean lumen diameter ( −0.029 mm for Artery 1; −0.043 mm for Artery 2), and root mean square error was small (0.063 mm for Artery 1; 0.098 mm for Artery 2), and the mean absolute relative error was also low (1.75% for Artery 1; 2.31% for Artery 2). In conclusion, this proof-of-concept study in two patient-specific 3D coronary anatomies suggests that the proposed SDM-based simulations can achieve overall agreement with FEM, while substantially reducing computational time and mesh size.

6 July 2026 in Turkish Journal of Internal Medicine
Verified
Journal Article
Closed access
AAAdeola Adegunle
Adeola Adegunle
KAKanishk Aggarwal
Kanishk Aggarwal
RVRaj Vaibhav
Raj Vaibhav
YTYash Vardhan Trivedi
Yash Vardhan Trivedi
RJRohit Jain
Rohit Jain
NSNitasa Sahu
Nitasa Sahu
Interstitial lung diseases (ILDs) are a heterogeneous group of fibrotic and inflammatory lung disorders characterized by restrictive physiology and impaired gas exchange. However, emerging evidence suggests that ILD is a multisystem disorder with significant cardiovascular involvement extending beyond pulmonary hypertension (PH). Cardiac complications, including right ventricular (RV) remodeling, left ventricular (LV) dysfunction, heart failure with preserved ejection fraction (HFpEF), ischemic heart disease, and arrhythmias contribute substantially to morbidity and mortality. Pulmonary hypertension remains the most studied cardiac complication, with prevalence estimates ranging from 15% to >80% depending on disease severity and diagnostic modality. Chronic hypoxic vasoconstriction, capillary bed destruction, and endothelial dysfunction drive pulmonary vascular remodeling, leading to progressive RV pressure overload and maladaptive remodeling. However, recent data demonstrate a growing burden of LV dysfunction and heart failure. Large cohort studies show that heart failure independently predicts mortality in both IPF and non-IPF ILD populations. Global Burden of Disease analyses indicate a fivefold rise in ILD-associated heart failure prevalence over the past three decades, particularly among older adults. ILD has also been associated with increased risks of ischemic heart disease and myocardial infarction, independent of traditional cardiovascular risk factors. Arrhythmias—particularly atrial fibrillation and other atrial tachyarrhythmias—occur frequently and are associated with higher mortality, longer hospital stays, and increased healthcare costs. CTD-ILD populations demonstrate particularly elevated risks of heart failure, arrhythmias, and pulmonary arterial hypertension. Cardiac dysfunction—both right- and left-sided—substantially influences prognosis. Integrated cardiopulmonary assessment and early cardiovascular surveillance are essential to improve outcomes in ILD.

30 June 2026 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
WWWei Wu
Wei Wu
SZShijia Zhao
Shijia Zhao
CLChangkye Lee
Changkye Lee
YTYash Vardhan Trivedi
Yash Vardhan Trivedi
FRFarzad Rezaeicherati
Farzad Rezaeicherati
YCYiannis S. Chatzizisis
Yiannis S. Chatzizisis

11 July 2026 in Postgraduate Medicine
Verified
Journal Article
Closed access
ASArihant Senthil
Arihant Senthil
AGAarushi Gupta
Aarushi Gupta
VBVasu Bansal
Vasu Bansal
CACaroline Antony
Caroline Antony
YTYash Vardhan Trivedi
Yash Vardhan Trivedi
RJRohit Jain
Rohit Jain
Chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) are BCR:ABL1-driven hematologic malignancies that account for a substantial proportion of ...